NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Another reason that comes to mind for dropping temodar from nGBM patients treated with DCVax-L is that while temodar apparently reduces the regrowth of the remaining tumor, that further diminishment of the tumor after surgery may not be that important once DCVax-L is administered because the results of the phase 3 study have shown that DCVAx-L treated nGBM patients who have undergone suboptimal tumor resections, stood out in having a much better survival record than nGBM patients who have also undergone suboptimal tumor resections but only received temodar.